Ortho Regenerative Technologies CEO Philippe Deschamps says the company has reached the most significant milestone to date with the enrollment of its first patient in the US Phase I/II rotator cuff tear repair clinical trial.
The second patient in the trial has already been scheduled, with more to follow as it targets the end of September for the Phase 1 safety portion of the clinical program.
“What we’re doing now is working with potential development partners to look at who might help us after phase 2 to continue to develop this asset in both rotator cuff and other indications,” Deschamps said.
